Pain Therapeutics (PTIE) Downgraded by ValuEngine to “Strong Sell”
ValuEngine downgraded shares of Pain Therapeutics (NASDAQ:PTIE) from a sell rating to a strong sell rating in a research note released on Friday morning.
Separately, Zacks Investment Research cut Pain Therapeutics from a buy rating to a hold rating in a research report on Tuesday, September 19th.
Shares of Pain Therapeutics (NASDAQ PTIE) traded up $0.04 on Friday, hitting $4.06. The stock had a trading volume of 26,730 shares, compared to its average volume of 68,775. Pain Therapeutics has a 12-month low of $3.10 and a 12-month high of $9.31.
Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter. sell-side analysts predict that Pain Therapeutics will post -2.2 EPS for the current year.
A hedge fund recently bought a new stake in Pain Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in Pain Therapeutics, Inc. (NASDAQ:PTIE) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 59,989 shares of the biopharmaceutical company’s stock, valued at approximately $247,000. Dimensional Fund Advisors LP owned about 0.91% of Pain Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 36.16% of the company’s stock.
About Pain Therapeutics
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Ratings for Pain Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.